Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-10-25
2003-03-25
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S149000
Reexamination Certificate
active
06537990
ABSTRACT:
The present invention pertains to the field of neoplastic diseases theraphy. In particular, the present invention refers to the synergic anticancer effect displayed by an anthracycline derivative administered in combination with at least another pharmaceutical substance effective in anticancer theraphy.
Cancers are a leading cause of death in animals and humans; surgery, radiation and chemotherapy are the useful means to fight cancers.
In particular, combined chemotheraphy, designed to treat cancer by using more than one drug in combination or association, is a well accepted modality of treatment of neoplastic diseases.
Several efforts have been and are still being undertaken in order to select antitumor combinations more and more active and safe to be administered to a patient suffering from a cancer.
The increase of the antitumor efficacy of a known antitumor compound by administering the same in combination with one or more different antitumor compounds in order to obtain a therapeutic synergy, is a strongly felt need in the field of anticancer theraphy.
The present invention fulfill such a need by providing an anthracycline derivative which a is morpholinyl anthracycline, administered in combination with at least another pharmaceutical substance effective in anticancer theraphy, so that a synergistic effect can be revealed.
REFERENCES:
patent: 4710564 (1987-12-01), Otake et al.
patent: 5902809 (1999-05-01), Adekenov et al.
patent: WO 99/48503 (1999-09-01), None
patent: WO 00/15203 (2000-03-01), None
Y. Kishimoto, et al., Anti-Cancer Drugs, vol. 10, No. 3, pp. 267-273, “A Phase II Study Employing Combination Regimens Containing KRN8602 in Drug-Resistant Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”, Mar. 1999.
A. Hiroaka, et al., Japanese Journal of Cancer and Chemotherapy, vol. 26, No. 1, pp. 93-99, “Pilot Late Phase II Study of KRN8602 (MX2), A Novel Anthracycline Derivative, for Acute Leukemia—A Dose Finding Study in Combination”, Jan. 1999.
Y. Ohe, et al., Cancer Research, vol. 49, No. 15, pp. 4098-4102, “In Vitro Evaluation of the New Anticancer Agents KT6149, MX-2, SM5887, Menogaril, and Liblomycin Using Cisplatin-or Adriamycin-Resistant Human Cancer Cell Lines”, Aug. 1, 1989.
W. T. A. Van Der Graaf, et al., Cancer Chemotherapy and Pharmacology, vol. 35, No. 4, pp. 345-348, “The Role of Methoxymorpholino Anthracycline and Cyanomorpholino Anthracycline in a Sensitive Small-Cell Lung-Cancer Cell Line and its Multidrug-Resistant but P-Glycoprotein-Negative and Cisplatin-Resistant Counterparts”, 1995.
E. Alvino, et al., Cancer Chemotherapy and Pharmacology, vol. 40, No. 2, pp. 180-184, “In Vitro Antitumor Activity of 3'-Desamino-3' (2-Methoxy-4-Morpholinyl)Doxorubicin on Human Melanoma Cells Sensitive or Resistant to Triazene Compounds”, 1997.
R. N. Taub, et al., Proceedings of the Annual Meeting of the American Society of Clinical Oncology, vol. 16, p. A1831, “Phase II Study of Methoxymorpholinodoxorubicin in Advanced Sarcomas (PNU/S2243 (FCE 23762) )”1997.
P. A. Vasey, et al., Cancer Research, vol. 55, No. 10, pp. 2090-2096, “Phase I Clinical and Pharmacokinetic Study of 3'-Deamino-3'-(2-Methoxy-4-Morpholinyl) Doxorubicin (FCE 23762)”, May 15, 1995.
M. Watanabe, et al., Cancer Research, vol. 48, No. 23, pp. 6653-6657, “MX2, A Morpholino Anthracycline, As a New Antitumor Agent Against Drug-Sensitive and Multidrug-Resistant Human and Murine Tumor Cells”, Dec. 1, 1988.
M. Watanabe, et al., Cancer Research, vol. 51, No. 1, pp. 157-161, “Cellular Pharmacology of MX2, A New Morpholino Anthracycline, in Human Pleiotropic Drug-Resistant Cells”, Jan. 1, 1991.
F. Sola, et al., Cancer Chemoterapy and Phamacology, vol. 43, No. 3, pp. 241-246, “The Antitumor Efficacy of Cytotoxic Drugs is Potentiated by Treatment with PNU 145156E, A Growth-Factor-Complexing Molecule”, 1999.
Caruso Michele
Geroni Maria Cristina
Ripamonti Marina
Suarato Antonino
Anderson Rebecca
McDonnell & Boehnen Hulbert & Berghoff
McKane Joseph K.
Pharmacia Italia S.p.A.
LandOfFree
Combined preparations comprising morpholine anthracyclines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined preparations comprising morpholine anthracyclines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined preparations comprising morpholine anthracyclines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3005567